Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Best Amusement Park Bite: What Do You Very much want to Crunch On? - 2What loving-kindness meditation is and how to practice it in the new year
- 3'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- 4US FDA approves Kura-Kyowa's blood cancer therapy
- 5Mother and Stepson Rescued After Being Swept Over 6 Miles in Paddleboarding Mishap
- Three arrested in Paris after attempted bomb attack outside Bank of America
- Woman shocked to welcome baby after experiencing stomach pain on Christmas
- Northern lights chances rise for Christmas as space weather remains unsettled
- Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
- Former elite Australian soldier charged with Afghan war crimes
- Quandoo to shut restaurant booking platform by end of 2026
- The Best Web-based Courses for Ability Advancement
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
